Fludarabine

For research use only. Not for use in humans.

目录号:S1491 别名: FaraA, Fludarabinum 中文名称:氟达拉滨

Fludarabine Chemical Structure

CAS No. 21679-14-1

Fludarabine (FaraA, Fludarabinum)在血管平滑肌细胞中是一种STAT1活化抑制剂,特异性降低STAT1蛋白质水平(和mRNA水平) ,而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。

规格 价格 库存 购买数量  
RMB 810.59 现货
RMB 2525.07 现货
RMB 3836.33 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Fludarabine发表文献82篇:

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述 Fludarabine (FaraA, Fludarabinum)在血管平滑肌细胞中是一种STAT1活化抑制剂,特异性降低STAT1蛋白质水平(和mRNA水平) ,而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。
靶点
STAT1 [4]
(Vascular smooth muscle cells)
体外研究

Fludarabine有效抑制RPMI8226细胞增殖,呈时间浓度依赖性。Fludarabine处理MM.1S和MM.1R细胞48小时的IC50分别为13.48μg/mL和33.79μg/mL。而Fludarabine处理U266细胞48小时的IC 50为222.2μg/mL。Fludarabine处理可增加处于细胞周期G 1期的细胞数量,并伴随着处于细胞周期S期细胞数量的减少,对细胞周期的影响呈时间依赖性。Fludarabine在MM细胞中诱导细胞周期阻滞和细胞凋亡。Fludarabine时间依赖性的诱导caspase,-8,- 9和- 3,- 7的剪切,继而诱导PARP的剪切 。氟达拉滨以时间梯度增加Bax基因表达,而Bak基因表达量不变。RPMI 8226细胞用Fludarabine处理12小时,处理后细胞膜电位降低,61.05%的细胞表达低荧光罗丹明123,而未处理的对照组细胞仅为8.62%[1]。为提高溶解度,Fludarabine可制为一磷酸盐形式(F-ara-AMP, fudarabine),在静脉滴注后即可即时、定量的从母核上去磷酸化。细胞内重磷酸化修饰导致Fludarabine-阿糖胞苷三磷酸((F-ara-ATP)。该代谢产物抑制了DNA复制的几个关键过程,如DNA合成所需酶,比如核糖核酸还原酶,DNA引发酶,DNA聚合酶,具有3 ' - 5 '外切酶活性的脱氧核糖核酸聚合酶δ和ε和DNA连接酶[2]。通过检测ICAM - 1的表达和IL - 8释放,表明Fludarabine还可以诱导前炎症刺激单核细胞的增加[3]。Fludarabine对卵巢癌细胞系生长无影响,而它对黑色素瘤细胞系有明显的剂量依赖性抑制[4]。Fludarabine诱导显著降低STAT - 1磷酸化,但不改变JAK 2活性。磷酸Fludarabine对三种STAT蛋白磷酸化影响不显着。Fludarabine(1.5mg)在处理2天后和7天后显著降低磷酸化STAT - 1和STAT-1总蛋白量[5]。 磷酸化JAK 2在处理后第2天变化不明显,处理后第7天的JAK表达明显受抑制。Fludarabine不影响其他STAT蛋白质,特异性抑制STAT - 1激活以降低血管平滑肌细胞体外增殖。[5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Jeko-1  MlO3SpVv[3Srb36gRZN{[Xl? M2TkfVIxKM7:TR?= M13SNVI1KGh? MVPpcohq[mm2czDlfJBz\XO|aX;uJI9nKEmGTx?= NXLVfVNLOjV7NEC3NVI>
MV-4-11 MVnBdI9xfG:|aYOgRZN{[Xl? NV;DNGo2Oi53IN88US=> M3;BZ|Q5KGh? MWrpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NYLsXopROjVzMUG1PFM>
THP-1 NIHVT2dCeG:ydH;zbZMhSXO|YYm= NVPZU3F1Oi53IN88US=> M1\nSFQ5KGh? NFvOTlFqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NWXjU45mOjVzMUG1PFM>
MOLM 13 NF7iOm5CeG:ydH;zbZMhSXO|YYm= MWOyMlUh|ryP NIfmVWg1QCCq MWjpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= NXzKUJZJOjVzMUG1PFM>
KBM3/Bu2506 MWLBdI9xfG:|aYOgRZN{[Xl? MX[yMlUh|ryP MkDJOFghcA>? MXXpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MWqyOVEyOTV6Mx?=
Nalm-6 M1XBXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnuzTWM2OD1zODFOwG0> NEjPbmwzPTB4MUGwNS=>
Reh M3v3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXscZBKSzVyPUOwJO69VQ>? NWWxUmZROjVyNkGxNFE>
U2937 Mnn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlz5TWM2OD1zNjFOwG0> NGW5UJczPTB4MUGwNS=>
Mec-1 NV\HZ5RvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|Ux97zgNUCwJO69VQ>? NFjt[lQzPTB4MUGwNS=>
RPMI-8226 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq5[JFKSzVyPUWwNEDPxE1? NEm1N4UzPTB4MUGwNS=>
Molt-4 Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF6MDFOwG0> MmHENlUxPjFzMEG=
Nalm-6-FluR M4T5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrmZ4ZrUUN3ME2yOVAh|ryP NF[1V3czPTB4MUGwNS=>
Raji  NE\FZlJHfW6ldHnvckBCe3OjeR?= MWCzxsDPxE1? NX7Cc5NXOjRxNEivO|IhcA>? M2PoNYlv\HWlZYOgZYNkfW23bHH0bY9veyCxZjDwOVMtKHB4MzDhcoQheDd|wrC= MoHxNlQ6PDB4OUW=
PBMC MmTKSpVv[3Srb36gRZN{[Xl? MXy1NE8yODBizszN NHHoWlYzPCCq M4DxUmROW09? NVnNR2ZtcW6qaXLpeJMhW1SDVEGgdIhwe3Cqb4L5cIF1cW:w MYWyOFkyOTh5Mh?=
MDA-231 MXzGeY5kfGmxbjDBd5NigQ>? NVvjOWczOTByIN88US=> M37mbFI1KGh? NE[3U45FVVOR NID0[3hl\WO{ZXHz[ZMhUUSRIHX4dJJme3Orb36= NUTWXZJXOjR7MUG4O|I>
624.38mel  M2rkRWZ2dmO2aX;uJGF{e2G7 NH7xb3c2OCEQvF2= NH3QTZIzPCCq MX\EUXNQ MY\k[YNz\WG|ZYOgTWRQKGW6cILld5Nqd25? NGLORnIzPDlzMUi3Ni=>
MDA-231 MXnGeY5kfGmxbjDBd5NigQ>? NXvjTZlpPTBvMkCwJO69VQ>? NU\hT49COjRiaB?= M1HJdWROW09? MYTpcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? NHLac5gzPDlzMUi3Ni=>
624.38mel  MoPJSpVv[3Srb36gRZN{[Xl? Mn\jOVAuOjByIN88US=> M2\nRVI1KGh? NXq0bpdsTE2VTx?= MV\pcohq[mm2czDJSG8h[WO2aY\peJkhcW6mZYDlcoRmdnSueTDv[kBuWk6DIHzleoVtew>? MnW2NlQ6OTF6N{K=
HMECs NVPjRYR3TnWwY4Tpc44hSXO|YYm= NHntcoMyODEEoN88UeKh NELJO5Q{PsLiaB?= MkTSbY5pcWKrdIOgTWZP|rQEoHHu[EBNWFNiaX7keYNm\CCVVFHUNUBxcG:|cHjvdplt[XSrb36gZY5lKEmURkGg[ZhxemW|c3nvci=> NIfYOJIzPDJzMUOyOy=>
HMECs  NXXaOWNZTnWwY4Tpc44hSXO|YYm= MUWxNFDDqM7:TdMg NWnJbo55OzcEoHi= NV;VUINWcW6qaXLpeJMhUU[QzsJCpI1m\GmjdHXkJJBpd3OyaH;yfYxifGmxbjDv[kBUXEGWMTDhcoQhW1SDVEOsJIJ2fCCwb4Sgc4YhW1SDVEK= MkTvNlQzOTF|Mke=
BJAB NY\QdWlUSXCxcITvd4l{KEG|c3H5 NUfzfm5jPcLizszN NUP3VVR3OjRiaB?= NIXqNIhqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MYmyOFA2PzF2Nx?=
I-83 M3fNSWFxd3C2b4Ppd{BCe3OjeR?= M1PvV|XDqM7:TR?= MnLMNlQhcA>? NHjxT2ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MV2yOFA2PzF2Nx?=
NALM6 MVTBdI9xfG:|aYOgRZN{[Xl? MkfoOeKh|ryP MojvNlQhcA>? M3vnU4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MXyyOFA2PzF2Nx?=
DU-145 NWr4NWpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVz6SIpkOC1zMDFOwIcwdWx? NI\Pb5c1QCCqwrC= M3rUUolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MnzBNlM4OzR6MUW=
Nalm-6 NVXVSYZKTnWwY4Tpc44hSXO|YYm= NFXWbYQyOMLizszN NXzzZ4xJOS9{L{SgbC=> NYTjRVd7cW6mdXPld{BifXSxcHjh[5k> NGnDdHUzOzZ6MUKyNy=>
Reh NUfROZdrTnWwY4Tpc44hSXO|YYm= NXjodo44OTEEoN88US=> NFG5OHIyNzJxNDDo NGC0SHhqdmS3Y3XzJIF2fG:yaHHnfS=> MmT5NlM3QDF{MkO=
Nalm-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHITWM2OCEkiMyxNQKBkc7:TR?= NWXscnNXOjN4OEGyNlM>
Reh M2jTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPyTWM2OCEkiMyxNQKBkc7:TR?= NUTacJFVOjN4OEGyNlM>
HEC1A MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWOxNFAuPTByIN88US=> NIjafXkzPCCq MYjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MoPPNlM2QTV4OUe=
AN3CA M1yzT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\vRoJjOTByLUWwNEDPxE1? M{H1SlI1KGh? MYnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Ml20NlM2QTV4OUe=
HEC50B NYrZbGJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnmXlQyODBvNUCwJO69VQ>? Mlz2NlQhcA>? MkfYbY5pcWKrdIOgZ4VtdCCpcn;3eIghe2yrZ3j0cJk> NIDuRokzOzV7NU[5Oy=>
HEC1A MlrLRZBweHSxc3nzJGF{e2G7 NXTTcYt7OjBxMUCwJO69VQ>? MWiyOEBp NVn0S2F2cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NITlO|UzOzV7NU[5Oy=>
AN3CA NV36OI9oSXCxcITvd4l{KEG|c3H5 MkfnNlAwOTByIN88US=> NV\LSGhuOjRiaB?= M2nXZolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NEjnRWIzOzV7NU[5Oy=>
HEC50B MVPBdI9xfG:|aYOgRZN{[Xl? MUmyNE8yODBizszN NFe1TFczPCCq NEi4SW1qdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=> NVTxWZk4OjN3OUW2PVc>
EHEB M1WzcWFxd3C2b4Ppd{BCe3OjeR?= NEXkdGE1OCEQvF2= NYPIN4h3OjRiaB?= MU\pcoR2[2W|IHHwc5B1d3Orcx?= NWPtdo1TOjN2OUewO|U>
A549 M4DoU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3[yUWlEPTB;MUWuO:KyOi56INM1US=> NXTkO5RIOjN|N{exPVI>
A549 GAPDH-deficient MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nEWGlEPTB;MUiuOeKyOi5|INM1US=> MVKyN|M4PzF7Mh?=
CLL  NVTOUJhYSXCxcITvd4l{KEG|c3H5 NVTLOG85OTBizszNxsA> Mn\SNlQuQTZiaB?= MmT6bY5lfWOnczDhdI9xfG:2aXOgZ4VtdCCmZXH0bC=> M3:xPVIzOjB5Nki2
MEC1 NGPT[VFCeG:ydH;zbZMhSXO|YYm= M{HFVlExOMLizszN NWrKRpMzPzJiaB?= MmnMbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgQ>? NUnpUnE{OjJzM{K5O|M>
U937  MYjBdI9xfG:|aYOgRZN{[Xl? NXrTTWgxOC56IN88US=> MkHEOE01QCCq MXnpcoR2[2W|IHHwc5B1d3OrczDzcIlocHSueR?= MUSyNlA4PDdyMB?=
U937  MVvBdI9xfG:|aYOgRZN{[Xl? MUWxJO69VQ>? M{DEUVk3KGh? M3vIWYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 NF\uZ2EzOjB{M{WyNy=>
Daudi MVXBdI9xfG:|aYOgRZN{[Xl? MkDXNlAh|ryP MYm5OkBp M3y4XIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5 M{K3blIzODJ|NUKz
J45.01 MX;BdI9xfG:|aYOgRZN{[Xl? NYrYWmtjOSEQvF2= MXW5OkBp Ml7qbY5lfWOnczDhdI9xfG:|aYOgd4xq\2i2bIm= MWeyNlAzOzV{Mx?=
RPMI 8226 M2LUTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYX3eJY6UUN3ME2yOU46yqEEsdMgN{44KM7:TR?= Mo\PNlE6PDh{NkS=
CEM MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7GUGhYUUN3ME2yMlTDqMLzwrCwMlQh|ryP NGDDcHgzOTl2OEK2OC=>
Raji MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjWWXZKSzVyPUCuOFfDqMLzwrCwMlA1KM7:TR?= MlPDNlE6PDh{NkS=
U937 M4[3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLDbFJrUUN3ME2wMlI1yqEEsdMgNE4xPCEQvF2= NUnTbWd6OjF7NEiyOlQ>
K562 NETRSJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNEVCpOKyyqByLkC1JO69VQ>? MlnDNlE6PDh{NkS=
NALM-6 NYC3NYhuSXCxcITvd4l{KEG|c3H5 M3ziUFExKM7:TdMg NFjaSoUzPCCq M4fISYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl? MUCyNVY6QTN6Mx?=
JMV-3 NFiweZFCeG:ydH;zbZMhSXO|YYm= M17uelExKM7:TdMg MoCxNlQhcA>? MkKxbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|bHnnbJRtgQ>? MlL5NlE3QTl|OEO=
EHEB M13vcWZ2dmO2aX;uJGF{e2G7 MVy1MVUxKM7:TR?= NHu4U|UzPCCq MX\k[YNz\WG|ZYOgdFIyKGW6cILld5Nqd25ic3nncolncWOjboTsfS=> MoXPNlEyPjh|OUG=
JVM-2  M175NGZ2dmO2aX;uJGF{e2G7 NVnVcmdWOzBizszN NUHDXnRxOjRiaB?= MkP5[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:w NVzxW481OjFzNkizPVE>
KBM3/Bu2506 NW\kUo06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDLeYJKSzJyPUCuOlchyrWP MXyyNFk{OzVyOR?=
KBM3/Bu2506 MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3nOR|AvPiEQvF2= NX;DS|YzOjRiaB?= MVnpcoNz\WG|ZYOgeIhmKGOnbHyg[pJi[3Srb36gbY4hWy2yaHHz[S=> NUiyO|d1OjB7M{O1NFk>
MDA-MB-231 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDJSY56UUN3ME20MlAh|ryP NX\2N2xSOjB2NEezPVA>
MCF-7 NHvyXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7YTWM2OD1zNT6wJO69VQ>? M3jTeFIxPDR5M{mw
HLE-B3  NFKwdlhHfW6ldHnvckBCe3OjeR?= MX6yOUDPxE1? M3:1VlQ5KGh? NF\mTlZjdG:la4OgTWZPNc7|4pETbY5lfWOnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44h[W6mIFnEU{BmgHC{ZYPzbY9v Mk\3NlA1OzVzNUi=
K562 MlLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXTO|IhcA>? MoTDTWM2OD1|LkOgcm0> MVeyNFMxPzF7OB?=
BW-225 NXX2e4dGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|IxRTFwM{egx7cyOOLKkklCpO69VcLi NHvxdGcyQDZ4MUO4NC=>
OH-65 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf4Wmg4UUN{ME2xMlM4KMPZMUFijLI5yqEQvF5CpC=> NIjXUooyQDZ4MUO4NC=>
GR-145 NEDHcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\rO2lKSzJyPUKuO|Qhy5diMUFijLI5KCEQvF5CpC=> MY[xPFY3OTN6MB?=
A549 NX[xVVFET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fNdmlEOjB;NT60PEDEnyBzMPMIllgh|ryPwrC= NI\hPHUyQDZ4MUO4NC=>
CaSki  MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrsWHZpUUN{ME2xMlM4KMPZIEGw5qiTPyEQvF5CpC=> MlfwNVg3PjF|OEC=
ZMK-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFz1Um9KSzJyPUGuN|chy5diMUFijLI3KM7:TdMg MV:xPFY3OTN6MB?=
SKW6.4 M{nFV2Fxd3C2b4Ppd{BCe3OjeR?= MXOwMlAyNTFyIN88US=> NWrWRpc4OjRxNEigbC=> NXrRTHlJcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= M3zpNVE5ODl{M{Sw
RPMI 8226 NY\YSFRWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLVemEzPCCq M2nEfmlEPTB;MT61OOKh|ryP M4LWOVE4QTd4MUi2
MM.1S MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfOPIk1QCCq NUOwfWdXUUN3ME2xN{41QMLizszN NVn2O5BvOTd7N{[xPFY>
MM.1R NIPzNG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHwe3Q1QCCq M4XWTGlEPTB;M{OuO|kh|ryP NHLER2EyPzl5NkG4Oi=>
U937 NVXaWlFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjqTWM2OD1|LEKwNEDDuSB3NkCgcm0> NXjXW3RzOTV7M{CzOlE>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
procaspase-9 / procaspase-3; 

PubMed: 27223263     


Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control.

p-p53 / p53; 

PubMed: 27223263     


(A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒

STAT1; 

PubMed: 26677135     


Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.

27223263 26677135
Immunofluorescence
α-SMA / Vimentin; 

PubMed: 28322315     


FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).

28322315
Growth inhibition assay
Cell viability ; 

PubMed: 24956101     


CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.

24956101
体内研究 PBS对照组中肿瘤细胞增长迅速,25天内扩增为10倍。而用40mg/kgFludarabine处理的肿瘤扩增不超过5倍。40mg/kgFludarabine对RPMI 8226细胞有明显的抗肿瘤效果。RPMI 8226处理肿瘤细胞十天后增加凋亡细胞核数量。[1] Fludarabine可在免疫缺陷小鼠中有效抑制RPMI 8226细胞的骨髓转移。

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

- 合并
  • Cell lines: 地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系
  • Concentrations: 2 μg/Ml
  • Incubation Time: 24 小时
  • Method:

    对地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系以5 × 105细胞密度铺板,实验组均包括氟达拉滨处理和空白对照组。处理后细胞用PBS清洗两次然后用70%冰乙醇固定,离心后用含100μg/mL核糖核酸酶PBS重悬浮,37ºC孵育30分钟。样品重悬于25μg/mL碘化吡啶中,用流式细胞仪检测。根据产品说明用Annexin V-FITC试剂盒检测细胞凋亡。利用TUNEL(末端脱氧核苷酸转移酶介导脱氧核苷酸缺口末端标记)法和原位细胞凋亡检测试剂盒处理细胞,最后用流式细胞仪分析。


    (Only for Reference)
动物实验:

[1]

- 合并
  • Animal Models: 携带RPMI 8226肿瘤细胞的免疫缺陷型小鼠
  • Dosages: 40 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 57 mg/mL (199.83 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% propylene glycol, 5% Tween 80, 65% D5W
30 mg/mL (suspension)

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 285.23
化学式

C10H12FN5O4

CAS号 21679-14-1
储存条件 粉状
溶于溶剂
别名 FaraA, Fludarabinum

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04526795 Not yet recruiting Drug: Cytarabine|Drug: Fludarabine|Drug: Pegcrisantaspase Blast Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Recurrent Acute Biphenotypic Leukemia|Recurrent Acute Lymphoblastic Leukemia|Recurrent Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive|Recurrent T-Cell Prolymphocytic Leukemia|Refractory Acute Biphenotypic Leukemia|Refractory Acute Lymphoblastic Leukemia|Refractory Acute Myeloid Leukemia|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive|Refractory T-Cell Prolymphocytic Leukemia M.D. Anderson Cancer Center|National Cancer Institute (NCI) December 31 2020 Phase 1
NCT03832127 Not yet recruiting Drug: 18F-Fludarabine Myeloma Nantes University Hospital|Cyceron April 1 2019 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    how to re-suspend and deliver the inhibitor for in vivo experiments?

  • 回答:

    For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

STAT Signaling Pathway Map

相关STAT产品

Tags: 购买Fludarabine | Fludarabine供应商 | 采购Fludarabine | Fludarabine价格 | Fludarabine生产 | 订购Fludarabine | Fludarabine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID